Wei F, Huang Q, He J, et al. - Researchers sought to compare results between lenvatinib plus camrelizumab therapy and lenvatinib monotherapy when administered as post-progression treatment for advanced hepatocellular carcinoma (HCC) with progressive disease (PD) in this retrospective study. There were 48 advanced HCC patients who were included herein. Participants were split into the lenvatinib plus camrelizumab group (n = 21) and the lenvatinib group (n = 27). The median overall survival was not obtained. A significantly longer median progression-free survival was seen in the lenvatinib plus camrelizumab group vs lenvatinib group. Higher objective response rate as well as disease control rate were observed in lenvatinib plus camrelizumab group vs lenvatinib group. Occurrence of grade ≥ 3 adverse events was evident in 23.81% of patients in the lenvatinib plus camrelizumab group and in 25.93% of patients in the lenvatinib group. Overall, findings demonstrate the effectiveness as well as the safety of lenvatinib plus camrelizumab as post-progression treatment for advanced hepatocellular carcinoma with PD.